logo
Hot flush pill for menopausal women approved for use in UK

Hot flush pill for menopausal women approved for use in UK

Independent08-07-2025
Women in the UK will soon have access to a new daily pill designed to alleviate hot flushes during menopause, following its approval for use.
The Medicines and Healthcare products Regulatory Agency (MHRA) has become the first global regulator to give the green light to elinzanetant, also known as Lynkuet.
Developed by Bayer, this treatment offers an alternative to hormone replacement therapy (HRT) for those experiencing vasomotor symptoms, commonly known as hot flushes.
HRT is currently a widely used option for managing various menopause and perimenopause symptoms, including these disruptive flushes.
But not all patients want or are able to take hormone treatments.
At present elinzanetant is not available on the NHS but the green light from the MHRA means that it can be purchased privately in the UK.
It is to be considered by the NHS spending watchdog, the National Institute for Health and Care Excellence.
Hot flushes and night sweats are one of the most common symptoms of menopause.
It is understood that as oestrogen levels decline around menopause, the body's temperature regulation system can be disrupted when certain brain cells become overactive.
The new treatment, which is a non-hormonal medication, works by calming these signals in the brain.
Clinical trial data showed that the drug was safe and well tolerated and reduced hot flushes compared with a dummy drug, also known as a placebo.
It was also linked to fewer sleep disturbances and women taking it reported a better quality of life compared with those taking the placebo.
'Hot flushes and night sweats associated with menopause can have a significant negative impact on quality of life,' said Julian Beach, the MHRA's interim executive director of healthcare quality and access.
'We are therefore pleased to announce our approval of elinzanetant, which has met the MHRA's standards for safety, quality and effectiveness.
'Elinzanetant offers a non-hormonal alternative for those who may not be able to, or prefer not to, take hormone-based therapies.
'As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used.'
Women usually go through the menopause when they are aged between 45 and 55, though it can start sooner.
During the menopause a woman's periods stop due to lower hormone levels.
Menopause and perimenopause can cause symptoms including anxiety, mood swings, brain fog, hot flushes and irregular periods.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gonorrhoea vaccine becomes available at sexual health clinics in England
Gonorrhoea vaccine becomes available at sexual health clinics in England

Glasgow Times

time6 minutes ago

  • Glasgow Times

Gonorrhoea vaccine becomes available at sexual health clinics in England

The vaccination programme is expected to save the NHS £7.9 million over the next decade and combat increasing levels of antibiotic-resistant strains of the disease. The move aims to tackle rising levels of the sexually transmitted infection (STI) after cases in England topped 85,000 in 2023, the highest since records began in 1918. The free jab will be on offer from Monday to patients at the highest risk of the sexually transmitted infection, including gay and bisexual men with a recent history of multiple sexual partners or a bacterial STI. The vaccine is an existing jab, known as 4CMenB, that is currently used to protect people against the meningococcal B disease, a serious bacterial infection that can cause meningitis and sepsis. It is used in the routine childhood programme and given to babies at eight weeks, 16 weeks and one year. The programme is targeted to those most at risk and could prevent up to 100,000 cases. Gonorrhoea disproportionately impacts specific communities, such as those in deprived areas, people of black Caribbean ethnicity, and gay, bisexual and other men who have sex with men, according to the Joint Committee on Vaccination and Immunisation (JCVI). Patients getting the gonorrhoea vaccine will also be offered jabs for mpox, human papillomavirus (HPV), and hepatitis A and B at their appointment. Ashley Dalton, the minister for public health and prevention, said: 'Rolling out this world-leading gonorrhoea vaccination programme in sexual health clinics in England represents a major breakthrough in preventing an infection that has reached record levels. 'This government's world-first vaccination programme will help turn the tide on infections, as well as tackling head-on the growing threat of antibiotic resistance. 'I strongly encourage anyone who is eligible to come forward for vaccination, to protect not only yourselves but also your sexual partners.'

Gonorrhoea vaccine becomes available at sexual health clinics in England
Gonorrhoea vaccine becomes available at sexual health clinics in England

South Wales Argus

time36 minutes ago

  • South Wales Argus

Gonorrhoea vaccine becomes available at sexual health clinics in England

The vaccination programme is expected to save the NHS £7.9 million over the next decade and combat increasing levels of antibiotic-resistant strains of the disease. The move aims to tackle rising levels of the sexually transmitted infection (STI) after cases in England topped 85,000 in 2023, the highest since records began in 1918. The free jab will be on offer from Monday to patients at the highest risk of the sexually transmitted infection, including gay and bisexual men with a recent history of multiple sexual partners or a bacterial STI. The vaccine is an existing jab, known as 4CMenB, that is currently used to protect people against the meningococcal B disease, a serious bacterial infection that can cause meningitis and sepsis. It is used in the routine childhood programme and given to babies at eight weeks, 16 weeks and one year. The programme is targeted to those most at risk and could prevent up to 100,000 cases. Gonorrhoea disproportionately impacts specific communities, such as those in deprived areas, people of black Caribbean ethnicity, and gay, bisexual and other men who have sex with men, according to the Joint Committee on Vaccination and Immunisation (JCVI). Patients getting the gonorrhoea vaccine will also be offered jabs for mpox, human papillomavirus (HPV), and hepatitis A and B at their appointment. Ashley Dalton, the minister for public health and prevention, said: 'Rolling out this world-leading gonorrhoea vaccination programme in sexual health clinics in England represents a major breakthrough in preventing an infection that has reached record levels. 'This government's world-first vaccination programme will help turn the tide on infections, as well as tackling head-on the growing threat of antibiotic resistance. 'I strongly encourage anyone who is eligible to come forward for vaccination, to protect not only yourselves but also your sexual partners.'

Gonorrhoea vaccine becomes available at sexual health clinics in England
Gonorrhoea vaccine becomes available at sexual health clinics in England

Leader Live

time36 minutes ago

  • Leader Live

Gonorrhoea vaccine becomes available at sexual health clinics in England

The vaccination programme is expected to save the NHS £7.9 million over the next decade and combat increasing levels of antibiotic-resistant strains of the disease. The move aims to tackle rising levels of the sexually transmitted infection (STI) after cases in England topped 85,000 in 2023, the highest since records began in 1918. The free jab will be on offer from Monday to patients at the highest risk of the sexually transmitted infection, including gay and bisexual men with a recent history of multiple sexual partners or a bacterial STI. The vaccine is an existing jab, known as 4CMenB, that is currently used to protect people against the meningococcal B disease, a serious bacterial infection that can cause meningitis and sepsis. It is used in the routine childhood programme and given to babies at eight weeks, 16 weeks and one year. The programme is targeted to those most at risk and could prevent up to 100,000 cases. Gonorrhoea disproportionately impacts specific communities, such as those in deprived areas, people of black Caribbean ethnicity, and gay, bisexual and other men who have sex with men, according to the Joint Committee on Vaccination and Immunisation (JCVI). Patients getting the gonorrhoea vaccine will also be offered jabs for mpox, human papillomavirus (HPV), and hepatitis A and B at their appointment. Ashley Dalton, the minister for public health and prevention, said: 'Rolling out this world-leading gonorrhoea vaccination programme in sexual health clinics in England represents a major breakthrough in preventing an infection that has reached record levels. 'This government's world-first vaccination programme will help turn the tide on infections, as well as tackling head-on the growing threat of antibiotic resistance. 'I strongly encourage anyone who is eligible to come forward for vaccination, to protect not only yourselves but also your sexual partners.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store